ZEJULA (niraparib) logo

Product menu

Fictious Healthcare Professional

Individualised starting dose

ZEJULA (niraparib) offers your patients an individualised starting dose, based on baseline weight and platelet counts1

Ensure your patients start on the recommended ZEJULA dose for them1-4

The ZEJULA starting dose is dependent on weight and baseline platelet levels:1

Image of ZEJULA (niraparib) 200 mg tablet Image of Zejula (niraparib) 300mg tablet

For patients with moderate hepatic impairment, the recommended starting dose of ZEJULA is 200 mg once daily, regardless of body weight.1

With ZEJULA individualised starting dose, potentially reduce the incidence of certain AEs vs fixed starting dose, without compromising on efficacy1-4*

Please see the SmPC for guidance on dosing related to hepatic or renal impairments and for further information on Zejula

*This analysis is exploratory in nature; it does not control for type 1 error and is not powered to determine treatment effect in any subgroup.

WHAT ABOUT ZEJULA EFFICACY?

WHAT ABOUT ZEJULA SAFETY?

Find out more

PRIME overview

PRIMA overview

PRIME study design

PRIMA study design

ZEJULA (niraparib) is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Abbreviations

AE, adverse event; FIGO, Federation of Gynaecology and Obstetrics; kg, kilogram; mg, milligram; μl, microlitre.

References

  1. Zejula (niraparib) Summary of product characteristics (Last Accessed: May 2024).
  2. Gonzalez-Martin A, et al, European Journal of Cancer, 189 (2023) 112908. doi:10.1016/j.ejca.2023.04.024
  3. González-Martín A, et al. N Engl J Med. 2019;381(25):2391–2402
  4. GSK, Inc. Data on file. 2020 [Niraparib Global Data Sheet].

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk (UK) or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to GSK Limited on 0800 221 441 or by email at uksafety@gsk.com.

©2024 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

May 2024 | PM-GB-NRP-WCNT-220024 (V2.0)